Search: onr:"swepub:oai:DiVA.org:umu-38999" > Effects of losartan...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04804naa a2200481 4500 | |
001 | oai:DiVA.org:umu-38999 | |
003 | SwePub | |
008 | 110114s2009 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:118618634 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-389992 URI |
024 | 7 | a https://doi.org/10.1097/HJH.0b013e32831daf962 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1186186342 URI |
040 | a (SwePub)umud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Olsen, Michael Hechtu Glostrup University Hospital, Glostrup, Denmark4 aut |
245 | 1 0 | a Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy :b the losartan intervention for endpoint reduction in hypertension (LIFE) study |
264 | 1 | c 2009 |
338 | a print2 rdacarrier | |
520 | a Objective: Beta-blockers and angiotensin II receptor blockers have different effects on lipids. Methods: We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke. We measured total and high-density lipoprotein cholesterol at baseline and annually during 4.8 years of losartan-based compared with atenolol-based treatment in 8611 patients with hypertension and left ventricular hypertrophy. Results: Patients randomized to losartan-based or atenolol-based treatment had similar baseline total (6.04 ± 1.12 vs. 6.05 ± 1.13 mmol/l, NS) and high-density lipoprotein (HDL) cholesterol (1.50 ± 0.44 vs. 1.49 ± 0.44 mmol/l, NS). Total cholesterol decreased significantly but equally (-0.37 ± 1.05 vs. -0.34 ± 1.09 mmol/l, NS), whereas HDL cholesterol decreased less during the first 2 years in patients randomized to losartan compared with atenolol (-0.13 ± 0.24 vs. -0.19 ± 0.25 mmol/l) and remained higher each year (1.38, 1.37, 1.42, 1.47, and 1.48 mmol/l vs. 1.32, 1.30, 1.36, 1.40, and 1.42 mmol/l, all P < 0.001) independent of hydrochlorothiazide or statin treatment. In Cox regression analysis, baseline total cholesterol [hazard ratio (HR) = 1.08 (1.02–1.14) per mmol/l, P < 0.01], HDL cholesterol [HR = 0.56 (0.48–0.66) per mmol/l, P < 0.001], and treatment allocation [HR = 0.86 (0.76–0.98), P < 0.05] predicted composite endpoint independently. Using time-varying analyses, the predictive strength of HDL cholesterol was increased [HR = 0.36 (0.30–0.44) per mmol/l, P < 0.001], whereas that of total cholesterol [HR = 1.03 (0.97–1.09) per mmol/l, NS] and treatment allocation [HR = 0.91 (0.80–1.03), NS] were reduced. Conclusion: Losartan blunted the decrease in HDL cholesterol during antihypertensive treatment in the LIFE study. Higher intreatment HDL cholesterol was associated with fewer composite endpoints and may partly explain the better outcome of losartan-based treatment. | |
700 | 1 | a Wachtell, Kristianu Rigshospitalet, Copenhagen, Denmark4 aut |
700 | 1 | a Beevers, Garethu City Hospital, Birmingham, UK4 aut |
700 | 1 | a Dahlöf, Björnu Sahlgrenska University Hospital/Östra, Göteborg, Sweden4 aut |
700 | 1 | a de Simone, Giovanniu Federico II University of Naples, Naples, Italy4 aut |
700 | 1 | a Devereux, Richard Bu Weill Cornell Medical College, New York City, New York, USA4 aut |
700 | 1 | a de Faire, Ulfu Karolinska Institutet4 aut |
700 | 1 | a Fyhrquist, Freju Helsinki University Central Hospital, Helsinki, Finland4 aut |
700 | 1 | a Ibsen, Hansu Glostrup University Hospital, Glostrup, Denmark4 aut |
700 | 1 | a Kjeldsen, Sverre Eu Ullevaal University Hospital, Oslo, Norway4 aut |
700 | 1 | a Lederballe-Pedersen, Oleu Viborg Hospital, Viborg, Denmark4 aut |
700 | 1 | a Lindholm, Lars Hu Umeå universitet,Allmänmedicin4 aut0 (Swepub:umu)lali0003 |
700 | 1 | a Lyle, Paulette Au Merck Research Laboratories, North Wales, Pennsylvania, USA4 aut |
700 | 1 | a Nieminen, Markku Su Helsinki University Central Hospital, Helsinki, Finland4 aut |
700 | 1 | a Omvik, Peru Haukeland University Hospital, Bergen, Norway4 aut |
700 | 1 | a Oparil, Suzanneu University of Alabama, Birmingham, Alabama, USA4 aut |
700 | 1 | a Wedel, Hansu Nordic School of Public Health, Gothenburg, Sweden4 aut |
710 | 2 | a Glostrup University Hospital, Glostrup, Denmarkb Rigshospitalet, Copenhagen, Denmark4 org |
773 | 0 | t Journal of Hypertensiong 27:3, s. 567-574q 27:3<567-574x 0263-6352x 1473-5598 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-38999 |
856 | 4 8 | u https://doi.org/10.1097/HJH.0b013e32831daf96 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:118618634 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view